key: cord-0763363-4y9l7vhf authors: Rich, Matthew D.; Sorenson, Thomas J.; Schubert, Warren title: Post‐surgical pyoderma gangrenosum in otherwise healthy patient with history of COVID‐19 date: 2021-05-24 journal: Breast J DOI: 10.1111/tbj.14242 sha: 3cd7fe47398b624d9df02ac7007f627b2d9fbd04 doc_id: 763363 cord_uid: 4y9l7vhf There are increasing reports of autoimmune and dermatologic sequelae of COVID‐19. We describe an otherwise healthy patient with recent history of serious COVID‐19 infection who developed post‐surgical pyoderma gangrenosum following bilateral reduction mammoplasty and was successfully treated with infliximab, mycophenolic acid, and corticosteroids. We present this case to highlight the lingering systemic proinflammatory effects of COVID‐19 infection that may increase the risk of rare autoimmune complications of surgery. As a complete understanding of the long‐term effects of COVID‐19 is poorly understood, patients with a history of COVID‐19 infection should be appropriately counseled to these possible risks when discussing surgery. Extrapulmonary manifestations of the novel Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19) are increasingly being reported. These manifestations are likely related to the proinflammatory effects of COVID-19 infection and its triggered cytokine release syndrome, which can result in serious cardiovascular, dermatologic, and autoimmune consequences. 1-4 Increasingly, researchers are also reporting possible prolonged consequences of the virus' proinflammatory effects, casually named "long COVID". [5] [6] [7] [8] [9] These lingering, dysregulated, proinflammatory consequences may increase an individual's susceptibility to inflammatory or autoimmune disorders. Post-surgical pyoderma gangrenosum is an uncommon inflammatory skin disorder of unknown etiology that has been previously reported after breast surgery [10] [11] [12] and is associated with underlying autoimmune conditions such as rheumatoid arthritis. In patients without these traditional underlying autoimmune conditions, postsurgical pyoderma gangrenosum has not yet been associated with COVID-19 viral infection or its possible lingering proinflammatory effects. In this case report, we describe the first case of post-surgical pyoderma gangrenosum after bilateral reduction mammoplasty in an obese, otherwise healthy, 44-year-old woman with a recent history of COVID-19 infection. We present the case of a 44-year-old obese (BMI: 46) otherwise healthy woman of East Indian descent, who initially presented to our hospital in May 2020 with progressive respiratory symptoms in the setting of a positive COVID-19 test. She was hospitalized and underwent a 5-day course of Remdesivir. The patient was discharged home on hospital day six with improvement of her symptoms. Three months later, the patient returned to our same day surgical center for a planned bilateral reduction mammoplasty. There are increasing reports of autoimmune and dermatologic sequelae of COVID-19. We describe an otherwise healthy patient with recent history of serious COVID-19 infection who developed post-surgical pyoderma gangrenosum following bilateral reduction mammoplasty and was successfully treated with infliximab, mycophenolic acid, and corticosteroids. We present this case to highlight the lingering systemic proinflammatory effects of COVID-19 infection that may increase the risk of rare autoimmune complications of surgery. As a complete understanding of the long-term effects of COVID-19 is poorly understood, patients with a history of COVID-19 infection should be appropriately counseled to these possible risks when discussing surgery. autoimmune, breast, COVID-19, dermatology, pyoderma gangrenosum for pyoderma gangrenosum. The recommendation was a punch biopsy and starting methylprednisolone. The final pathology returned as "neutrophilic abscess" with deeper acute/chronic inflammation. Once steroids were initiated, the patient improved both from a clinical as well as inflammatory marker standpoint. Following discharge, she was re-admitted to the hospital once due to concerns of further wound dehiscence. She was started on infliximab by her dermatologist and has showed slow but steady improvement of her wounds, Reduction mammoplasty is a common surgery for plastic surgeons to perform, though this procedure is not without known complication. 13 The complication experienced by our patient, post-surgical pyoderma gangrenosum, is very uncommon and typically reported in the setting of another underlying autoimmune conditions like inflammatory bowel disease or rheumatoid arthritis. 10 Though our patient did not have a chronic autoimmune condition, she did have a recent history of COVID-19, which has known long-term proinflammatory effects on the immune system and widespread sequelae. 1,5,6,14 At the time of surgery, our patient did not have any symptoms that suggested "long COVID," but persisting proinflammation may have been present without our knowledge. There are now suggestions for pre-operative workup of patients with previous COVID-19 infection to identify the presence of any long-standing smoldering effects, and these suggestions may prove useful in the future for identifying lingering proinflammatory conditions and preventing related complications. 15 Pending clinical improvement, more potent immunosuppression with infliximab or mycophenolic acid can be initiated. 16 In our patient, corticosteroids, mycophenolic acid, and infliximab were used with steady improvement in the patient's wounds and inflammatory markers. Delayed septal perforation as a complication of COVID-19: a case report COVID-19 wounds: unusual lower extremity bullae COVID-19 can present with a rash and be mistaken for dengue Prolonged adaptive immune activation in COVID-19: implications for maintenance of long-term immunity? Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients The severe acute respiratory syndrome Coronavirus nucleocapsid inhibits type I interferon production by interfering with TRIM25-mediated RIG-I ubiquitination Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study A systematic review of postsurgical pyoderma gangrenosum: identification of risk factors and proposed management strategy Pyoderma gangrenosum after breast surgery: a systematic review Pyoderma gangrenosum after breast surgery: diagnostic pearls and treatment recommendations based on a systematic literature review Standardizing the complication rate after breast reduction using the Clavien-Dindo classification Pathophysiology, transmission, diagnosis, and treatment of Coronavirus disease 2019 (COVID-19): a review Preparing previously COVID-19-positive patients for elective surgery: a framework for preoperative evaluation Diagnosis and treatment of pyoderma gangrenosum How to cite this article Post-surgical pyoderma gangrenosum in otherwise healthy patient with history of COVID-19 None. The authors have no conflicts of interest to declare. The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. https://orcid.org/0000-0001-6658-254X